Net proceeds from the IPO will be used to provide capital for the development of DFU technology which will include investment in additional clinical studies supporting the indication along with progressing regulatory filings build a European presence and implement the Group's sales strategy to sell the Group's DeepView® product into various targeted European jurisdiction build US distribution network and provide working capital. Due late June.īaltic Classifieds Group PLC, the leading online classifieds group in the Baltics, announced their intention to IPO and the intended publication of a registration document. Should BCG proceed with the IPO, the Company will apply for admission of its entire issued Ordinary Share Capital to the Premium Listing Segment of the LSE. Spectral MD Holdings, Ltd., a predictive analytics group that develops proprietary AI algorithms and optical technology for faster treatment decisions in wound care, announces its intention to IPO onto AIM. The company plans to raise up to £15m on Admission on AIM (through a placing of new and existing equity). Due date late June / early July. The Company provides flexible solutions proven at adding value as retailers transform stores, digital capabilities and operations suitable for modern retailing and profit improvement. Itim adds value by helping multi-channel retailers optimise their business and stores to improve financial performance and compete more effectively in the digital world of modern retailing. Itim Group Limited (to be renamed itim Group plc) is a software technology company, established in 1993. Orcadian plans to raise gross proceeds of c. The Company's key asset is the 100% interest in the Pilot oilfield, with audited proven and probable reserves of 78.8m barrels (audited by Sproule BV). Orcadian Energy, the North Sea focused, oil and gas development company, announces its intention to seek admission to AIM. Our daily digest of news from UK listed Small and Mid capsġ1 June corporate client of Hybridan LLPĬlarify Pharma (AQSE:PSYC), an investment vehicle specialising in biotech and life science companies seeking to prove the safety and efficacy of psychedelic-based substances, has commenced trading on the Access Segment of the AQSE Growth Market.£1.96m raised at 2.5p.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |